A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps
Study sponsor: Upstream Bio Inc. · UPB
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-07-07Actual
Enrollment · participants81Actual
Source updated2026-09-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.